Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

292 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase II study of bevacizumab, temozolomide, and hypofractionated stereotactic radiotherapy for newly diagnosed glioblastoma.
Omuro A, Beal K, Gutin P, Karimi S, Correa DD, Kaley TJ, DeAngelis LM, Chan TA, Gavrilovic IT, Nolan C, Hormigo A, Lassman AB, Mellinghoff I, Grommes C, Reiner AS, Panageas KS, Baser RE, Tabar V, Pentsova E, Sanchez J, Barradas-Panchal R, Zhang J, Faivre G, Brennan CW, Abrey LE, Huse JT. Omuro A, et al. Among authors: chan ta. Clin Cancer Res. 2014 Oct 1;20(19):5023-31. doi: 10.1158/1078-0432.CCR-14-0822. Epub 2014 Aug 8. Clin Cancer Res. 2014. PMID: 25107913 Free PMC article. Clinical Trial.
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers.
Morris LG, Taylor BS, Bivona TG, Gong Y, Eng S, Brennan CW, Kaufman A, Kastenhuber ER, Banuchi VE, Singh B, Heguy A, Viale A, Mellinghoff IK, Huse J, Ganly I, Chan TA. Morris LG, et al. Among authors: chan ta. Proc Natl Acad Sci U S A. 2011 Nov 22;108(47):19024-9. doi: 10.1073/pnas.1111963108. Epub 2011 Nov 7. Proc Natl Acad Sci U S A. 2011. PMID: 22065749 Free PMC article.
Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine-DNA methyltransferase as a potential biomarker.
Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, Travis WD, Heguy A, Ginsberg MS, Holodny AI, Chan TA, Rizvi NA, Azzoli CG, Riely GJ, Kris MG, Krug LM. Pietanza MC, et al. Among authors: chan ta. Clin Cancer Res. 2012 Feb 15;18(4):1138-45. doi: 10.1158/1078-0432.CCR-11-2059. Epub 2012 Jan 6. Clin Cancer Res. 2012. PMID: 22228633 Clinical Trial.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype.
Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, Chan TA. Turcan S, et al. Among authors: chan ta. Nature. 2012 Feb 15;483(7390):479-83. doi: 10.1038/nature10866. Nature. 2012. PMID: 22343889 Free PMC article.
Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.
Omuro A, Chan TA, Abrey LE, Khasraw M, Reiner AS, Kaley TJ, Deangelis LM, Lassman AB, Nolan CP, Gavrilovic IT, Hormigo A, Salvant C, Heguy A, Kaufman A, Huse JT, Panageas KS, Hottinger AF, Mellinghoff I. Omuro A, et al. Among authors: chan ta. Neuro Oncol. 2013 Feb;15(2):242-50. doi: 10.1093/neuonc/nos295. Epub 2012 Dec 14. Neuro Oncol. 2013. PMID: 23243055 Free PMC article. Clinical Trial.
292 results